Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice

作者：Matsumoto Sachiko; Shimabukuro Michio^*; Fukuda Daiju; Soeki Takeshi; Yamakawa Ken; Masuzaki Hiroaki; Sata Masataka

来源：Cardiovascular Diabetology, 2014, 13(1): 30.

DOI：10.1186/1475-2840-13-30

Background: Azilsartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), has a higher affinity for and slower dissociation from AT1 receptors and shows stronger inverse agonism compared to other ARBs. Possible benefits of azilsartan in diabetic vascular dysfunction have not been established. %26lt;br%26gt;Methods: We measured vascular reactivity of aortic rings in male KKAy diabetic mice treated with vehicle, 0.005% azilsartan, or 0.005% candesartan cilexetil for 3 weeks. Expression of markers of inflammation and oxidative stress was measured using semiquantitative RT-PCR in the vascular wall, perivascular fat, and skeletal muscle. Phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser(1177) and Thr(495) was measured using Western blotting, and the ratio of phosphorylation at Ser(1177) to phosphorylation at Thr(495) was used as a putative indicator of vascular eNOS activity. %26lt;br%26gt;Results: (1) Vascular endothelium-dependent relaxation with acetylcholine in KKAy mice was improved by azilsartan treatment compared to candesartan cilexetil; (2) the ratio of Ser(1177)/Thr(495) phosphorylation of eNOS was impaired in KKAy and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemotactic protein 1 (MCP1), F4/80, NAD(P) H oxidase (Nox) 2, and Nox4 of the aortic wall and in the expression of TNF alpha in the perivascular fat were strongly attenuated by azilsartan compared to candesartan cilexetil. %26lt;br%26gt;Conclusions: These results provide evidence that azilsartan prevents endothelial dysfunction in diabetic mice, more potently than does candesartan cilexetil. Azilsartan%26apos;s higher affinity for and slower dissociation from AT1 receptors may underlie its efficacy in diabetic vascular dysfunction via a dual effect on uncoupled eNOS and on Nox.

• 出版日期2014-1-31